Mecain (Mepivacaine Hydrochloride)

Mepivacaine blocks voltage‑gated sodium channels on nerve membranes, preventing sodium influx that is essential for depolarisation. By inhibiting nerve impulse generation and propagation, it temporarily halts sensory and motor signals, resulting in localized anaesthesia.

The dose of Mecain is determined by the prescribing clinician based on the specific procedure, patient weight, age, and health status. Dosage guidelines are provided in the product label, but the final regimen must be set by a qualified healthcare professional.

Safety data for mepivacaine in pregnancy and lactation are limited. It should only be used when the expected benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating obstetrician or physician.

To request Mecain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both mepivacaine and lidocaine are amide‑type local anesthetics, but mepivacaine has a slightly longer duration of action and a lower pKa, which can result in faster onset. Lidocaine is more widely used for short procedures, while mepivacaine is often preferred when a longer block is desired without vasoconstrictor addition.

Mecain should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture, direct sunlight and extreme temperatures. Do not freeze. Inspect the vial for particulate matter before use and discard if the solution appears discoloured.

Mecain is supplied as a sterile injectable solution and is administered by epidural, intradermal or intrathecal injection, depending on the clinical indication. The injection technique follows standard aseptic procedures, and the volume injected is determined by the treating clinician.

Serious adverse events include seizures, severe cardiac arrhythmias or arrest, anaphylactic reactions, and methemoglobinemia. Early signs of systemic toxicity such as tinnitus, metallic taste, or circumoral numbness should prompt immediate medical evaluation.

Mecain is contraindicated in patients with a known hypersensitivity to mepivacaine or other amide‑type local anesthetics, and in individuals with severe cardiac conduction disorders where local anesthetic toxicity could be life‑threatening. Caution is also advised for patients with significant hepatic impairment.